ArticleEJNMMI research2026
Preclinical in vivo dosimetry of healthy tissues in radiopharmaceutical therapy: implementation of a physiologically realistic mouse eye model in GATE.
Article in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundTargeted radionuclide therapy is a rapidly growing treatment modality that has shown great promise in managing metastatic cancers. However, the affinity of certain radiopharmaceuticals for off-target healthy tissues necessitates accurate dosimetric evaluations. This is especially the case for [131I]ICF01012, an experimental radiopharmaceutical used for advanced melanoma targeted radionuclide therapy, which targets melanin in pigmented tumors and metastases but also in melanized healthy tissues, including sensitive structures such as the retinal pigment epithelium. This study aimed to create the first anatomically precise, voxel-based mouse eye model to facilitate microdosimetric evaluations in the context of targeted radionuclide therapy. A voxelized model of the mouse eye was constructed using high-resolution MRI and SIMS imaging data from C57Bl/6J mice. The biodistribution of radioactivity in the eyes was assessed ex vivo by gamma counting. GATE Monte Carlo simulations were employed to calculate the S-values of the intraocular structures. Particular attention was given to the absorbed dose by the retina considering its proximity to the retinal pigment epithelium, which contains melanin.
resultsSIMS imaging revealed an increased iodine-127 signal in melanin-rich regions, particularly the retinal pigment epithelium and choroid. S values were obtained for all relevant source and target regions of the eye. Time-dependent biodistribution analysis of radioactivity revealed persistent retention of the radiotracer up to 21 days after injection. The retinal pigment epithelium received the highest dose, 24.14 Gy.MBq⁻¹, corresponding to an estimated absorbed dose by the retina of 6.91 Gy.MBq⁻¹.
conclusionThis work presents a novel dosimetry model for the mouse eye, providing essential insights into the exposure of melanin-rich tissues to iodine-131 radiation. Such models are necessary for optimizing therapeutic efficacy while minimizing toxicity in preclinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.